Recently, the interim results of the phase 3 KEYNOTE-811 trial (NCT#03615326) in enrolled patients with unresectable or metastatic, HER2-positive G/GEJ adenocarcinoma showed that first-line pembrolizumab plus trastuzumab and chemotherapy significantly reduced tumor size, induced CRs in some participants, and significantly improved ORR [8]. Here, ERBB2 is linked to neoplasm.